Magazine Article | July 1, 2020

Companies To Watch: Equillium

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Keeping a close eye on the COVID-19 challenge but sticking to acute graft-versus-host disease, uncontrolled asthma, and lupus nephritis as primary inflammation targets

SNAPSHOT

Bruce Steel
Equillium is developing its lead candidate, itolizumab, for autoimmune/inflammatory maladies: acute graft-versus-host disease (aGVHD), uncontrolled asthma, and lupus nephritis. Itolizumab targets the CD6-ALCAM (activated leukocyte cell adhesion molecule) inflammatory pathway to block activation and trafficking of effector T (Teff) cells and restore their natural balance with regulatory T (Treg) cells. A Phase 1b/2 trial in aGVHD is in progress, but the company’s Phase 1b uncontrolled asthma trial and Phase 1b lupus nephritis trial have been paused because of difficulties in institutional settings related to the COVID-19 pandemic.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: